Dr. AJ Troiano PhD, RBP, Global Director of Biosafety and Toxicology at FUJIFILM Diosynth Biotechnologies, explores whether organizations in multimodal CDMOs truly operate with a customer mindset and prioritize the health and safety of both workers and patients.

This webinar delves into our unique infrastructure for ensuring safety and quality in drug substance manufacturing. We focus on our new product introduction process, which is underpinned by a robust risk assessment and mitigation framework. Our approach prioritizes:

  • Customer-Centric Risk Management: We collaborate closely with customers throughout the manufacturing process to tailor risk management strategies to their specific needs.
  • Efficiency and Pragmatism: Our risk assessments focus on optimizing operational efficiency while implementing practical risk mitigation solutions.
  • Holistic Approach: We recognize the interconnectedness of safety, quality, and customer satisfaction, ensuring that each element is considered in our decision-making.

Whether you’re developing early-stage gene therapy or commercial-scale protein therapeutics, we are committed to partnering with you to deliver safe, high-quality products that meet your specific requirements.